News for Clinuvel Pharmaceuticals Limited (CLVLY)

First results of SCENESSE® study expected in 2H 2026 Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatol

**media[556210]**

Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q2 2025 Results Conference Call February 27, 2025 2:00 AM ETCompany ParticipantsStella Mariss - Monsoon...

CLINUVEL files Canadian New Drug Submission for SCENESSE ® in EPP

Start Time: 04:00 January 1, 0000 4:35 AM ETClinuvel Pharmaceuticals Limited (OTCPK:CLVLY)Q4 2024 Earnings Conference CallAugust 29, 2024, 04:00 AM...

The following slide deck was published by Clinuvel Pharmaceuticals Limited in conjunction with their 2024 Q4 earnings call.

Afamelanotide in fair-skinned Parkinson's patients

In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024.

Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q2 2023 Earnings Call Transcript February 22, 2024 2:00 AM ETCompany ParticipantsVerity Wai-Smith - Monsoon...

Clinuvel Pharmaceuticals Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net income was AUD 10.94 million compared to AUD 11.39...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.51% to 6925.50.

Read Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Decrease in Short Interest at ETF Daily News

Read Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update at ETF Daily News